Payment Coverage and Health Economics of SGLT2 inhibitors

Ngoc-Yen T. Pham; Christos P. Argyropoulos; Sireesha Koppula

doi:10.34067/KID.0000742021

Perspective

Payment Coverage and Health Economics of SGLT2 inhibitors

Ngoc-Yen T. Pham, Christos P. Argyropoulos and Sireesha Koppula

Kidney360 March 2021, 10.34067/KID.0000742021; DOI: https://doi.org/10.34067/KID.0000742021

Ngoc-Yen T. Pham

1University of New Mexico Hospitals, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christos P. Argyropoulos

2University of New Mexico School of Medicine, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Christos P. Argyropoulos
For correspondence: CArgyropoulos@salud.unm.edu

Sireesha Koppula

3Medicine, University of New Mexico Hospital, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Info & Metrics
View PDF

Abstract

This is an Early Access article. Please select the PDF button, above, to view it.

Sodium Glucose Cotransporter Two Inhibitors
Chronic Kidney Disease
Diabetic Kidney Disease
Coverage
Health Economics

Received February 19, 2021.
Revision received March 17, 2021.
Accepted March 17, 2021.

View the discussion thread.

PreviousNext

In this issue

Kidney360

Vol. 2, Issue 3

25 Mar 2021

Table of Contents
Table of Contents (PDF)
Cover (PDF)
About the Cover
Index by author

View Selected Citations (0)

Download PDF

Email Article

Thank you for your interest in spreading the word on American Society of Nephrology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Payment Coverage and Health Economics of SGLT2 inhibitors

Message Subject (Your Name) has sent you a message from American Society of Nephrology

Message Body (Your Name) thought you would like to see the American Society of Nephrology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Class Effects of SGLT2 inhibitors

Ngoc-Yen T. Pham, Christos P. Argyropoulos, Sireesha Koppula

Kidney360 Mar 2021, 10.34067/KID.0000742021; DOI: 10.34067/KID.0000742021

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Request Permissions

Class Effects of SGLT2 inhibitors

Ngoc-Yen T. Pham, Christos P. Argyropoulos, Sireesha Koppula

Kidney360 Mar 2021, 10.34067/KID.0000742021; DOI: 10.34067/KID.0000742021

Share This Article:

Tweet Widget
Facebook Like

Jump to section

Article
Info & Metrics
View PDF

Cited By...

No citing articles found.

Google Scholar

Keywords

Sodium Glucose Cotransporter Two Inhibitors
chronic kidney disease
diabetic kidney disease
Coverage
Health Economics

Main menu

User menu

Search

Payment Coverage and Health Economics of SGLT2 inhibitors

Abstract

In this issue

Citation Manager Formats

More in this TOC Section

Cited By...

Similar Articles

Related Articles

Keywords

Articles

Information for Authors

About

Journal Information

More Information